BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 28, 2013
View Archived Issues
Positive safety and efficacy data reported for ORM-12741 in phase IIa trial
Read More
Eisai's novel BACE1 inhibitor shows efficacy in reducing Abeta levels in vivo
Read More
SBI Pharmaceuticals' malignant glioma diagnostic approved in Japan
Read More
Trius' phase III tedizolid study in ABSSSI meets primary endpoint
Read More
Novel gene therapy may protect against Parkinson's disease
Read More
DNA-based epitope vaccine for AD tested in rabbits
Read More
Incyte Corp. patents novel PI3Kdelta inhibitors
Read More
IRM and Novartis divulge new PDGFR inhibitors
Read More
Osteoprotegerin as a predictor of mortality in CS complicating AMI
Read More
ReNeuron cleared to begin stem cell therapy trial in the U.K.
Read More
SymBio Pharmaceuticals begins phase I MDS trial in Japan
Read More
PICASSO 3 results lead ZIOPHARM Oncology to refocus development efforts
Read More
iBio to advance iBioLaunch-produced recombinant C1 inhibitor to clinical development
Read More
rhCDNF demonstrates improvement in MPTP mouse model of PD
Read More
Catabasis begins phase I trial of CAT-2003 for severe hypertriglyceridemia
Read More
Galapagos provides update on development portfolio
Read More
Takeda files for approval of lansoprazole/low-dose aspirin in Japan
Read More
Phytopharm provides update on strategic review
Read More
Scientists at Merck & Co. present new agents for hepatitis
Read More
Otsuka files NDA for multidrug-resistant tuberculosis drug in Japan
Read More
RedHill Biopharma and IntelGenx submit NDA for RHB-103 oral thin film
Read More
POZEN applies for FDA approval of PA-32540 and PA-8140
Read More
Aastrom Biosciences shifts focus
Read More
Novel PDE2A/PDE10A inhibitors patented by Lundbeck
Read More
EMA accepts ospemifene MAA
Read More
Pfizer obtains conditional marketing authorization for Bosulif in Europe
Read More
FDA approves Biogen Idec's Tecfidera as first-line oral treatment for MS
Read More